MediciNova, Inc.

Equities

MNOV

US58468P2065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-15 pm EDT			5-day change	1st Jan Change
1.49 ^USD	+0.68%		+10.37%	-0.67%

May. 14	MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	CI
May. 09	MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

MediciNova Inc. Announces Resignation of David O'Toole as Director

June 17, 2014 at 05:30 pm EDT

On June 16, 2014, David O'Toole resigned as a director of MediciNova Inc. pursuant to a resolution of the board of directors requiring the resignation of any director not receiving a majority of votes cast as a nominee for election for directors.

Latest news about MediciNova, Inc.

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	May. 14	CI
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	May. 07	CI
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	Mar. 26	CI
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	Mar. 12	CI
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	Jan. 17	CI
Top Premarket Gainers	Jan. 12	MT
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	Dec. 21	CI
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	Dec. 06	CI
Sector Update: Health Care Stocks Lean Down Premarket Monday	Nov. 20	MT
MediciNova Says Glioblastoma Phase 2 Trial of Therapy Combo Showed Progression-Free Survival of 44% at Six Months	Nov. 20	MT
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment	23-10-11	MT
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada	23-10-10	CI
MediciNova Says it Received $1 Million Clinical Development Milestone Payment Under Deal With Sanofi Subsidiary	23-10-05	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	23-09-28	MT
MediciNova Says Ibudilast Improved Pulmonary Function in Lung Injury Study	23-09-28	MT
MediciNova, Inc. Announces Results of Studies Under BARDA Contract to Develop MN 166 as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury	23-09-27	CI
MediciNova Announces Abstract Regarding MN-166 in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology	23-08-17	CI
MediciNova Says European Patent Office Issued Notice of Intention to Grant on Macular Injury Therapy Application	23-08-17	MT
MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 for the Treatment of Macular Injury in Europe	23-08-16	CI
Sector Update: Health Care Stocks Steady Premarket Wednesday	23-08-16	MT
Fed Minutes Anticipation Lifts Exchange-Traded Funds, Equity Futures Slightly Premarket Wednesday	23-08-16	MT
MediciNova Says European Patent Office Granted New Patent Covering Scleroderma, Systemic Sclerosis Treatment	23-08-16	MT

Chart MediciNova, Inc.

Duration

Period

More charts

Company Profile

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - American Society of Clinical Oncology Annual Meeting - Abstract Number: 2106

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.49 USD

Average target price

17 USD

Spread / Average Target

+1,040.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDICINOVA, INC.	-0.67%	72.59M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	111B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.58%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.54B
LEGEND BIOTECH CORPORATION	-23.95%	8.09B

Bio Therapeutic Drugs